Skip to content

A Perspective On Shire plc’s Successful Specialty Business Model: Rare Diseases And Orphan Drugs

August 1, 2012

         An Internet article that provides an interesting perspective on Shire plc’s successful specialty business model – rare diseases and orphan drugs, I am sharing with readers.  Many large biotechnology and pharmaceutical companies are buying smaller companies who have a niche in the rare disease and orphan drug market. 

        In light of all of the recent publicity of Shire plc’s Vpriv verses Genzyme’s Cerezyme in the Gaucher Disease market, this article provides an interesting perspective : July 31, 2012 Article titled, “Shire Takes Its Specialty Seriously”.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: